Delivery Order SPE2DB25D3404-SPE2DB26FULVY
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity, with a ceiling value of $1,809.72. This is a firm fixed-price delivery order with an ultimate completion date of October 24, 2025, and represents a non-set-aside competitive award. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (60 ml) with a ceiling value of $1,575.42. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The order is set for ultimate completion by September 3, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity. This is a firm fixed-price delivery order with a ceiling value of $3,763.02 and an ultimate completion date of July 28, 2025. The contract was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in 60 mL quantities, with a ceiling value of $3,991.48. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for ultimate completion by September 23, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities, valued at $4,567.35. This delivery order represents a firm fixed price, non-set-aside contract utilizing AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a delivery order valued at $2,477.61 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity. The contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award, and is scheduled for completion by August 26, 2025. The product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,909.60 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml) on September 10, 2025, with completion scheduled for September 11, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and is being performed at the awardee's corporate headquarters in Conshohocken, Pennsylvania. The contract is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 180ml quantities, with a ceiling value of $1,891.86. This firm fixed price delivery order, due for completion by October 31, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $2,915.25. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. The contract is scheduled for completion by June 3, 2025, with performance taking place at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity, valued at $2,724.02. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of October 24, 2025. The product will be supplied from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award represents a child delivery order issued under a larger indefinite delivery...
- SPE2DB25D3404Indefinite Delivery Contract
- SPE2DB25D3404-SPE2DB26FULVYDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 29, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in 60 mL quantities, with a ceiling value of $1,202.39. This firm fixed price delivery order, which will be completed by October 30, 2025, represents a non-competitive, open-market award supporting federal medical procurement needs. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves as a critical vendor for military and veteran healthcare systems, supplying an extensive portfolio of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. Quillivant XR, an extended-release ADHD medication, represents one example of the neurological and specialty pharmaceutical products the contractor regularly delivers to support Defense Health Agency and other federal healthcare customers through this comprehensive prime vendor vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 10/29/25 |